HPV HR, Screening 14 Types + Sample Adequacy Control (Rectal Mucosa Scraping)
Test for detecting high oncogenic risk HPV DNA (14 types) in rectal mucosa epithelial cells by PCR in screening format. Allows determination of high oncogenic type presence associated with precancerous and oncological change risk in the anorectal area. Includes sample adequacy control.
Biomaterial: Rectal mucosa epithelial cell scraping
Avoid anal sexual contact for 24 hours; do not use rectal suppositories, ointments, or enemas for 24-48 hours; perform hygiene without antiseptic agents on the test day.
Preventive examination of high-risk group individuals; presence of anogenital growths or chronic inflammatory processes; suspected HPV infection of the anorectal area; monitoring after HPV treatment; examination of partners of individuals with detected HPV infection.
Negative — high oncogenic risk HPV DNA not detected, sample adequacy control normal.
Positive — high oncogenic risk HPV DNA detected, physician consultation and additional examination required.
Important: a positive screening result does not mean presence of oncological disease.
